Sensei Biotherapeutics Inc - SNSE Net earnings per share for the last four quarters

Official company branding of Sensei Bio (SNSE)

Sensei Biotherapeutics (SNSE) faces clinical trial uncertainty and a reliance on external financing. The trailing twelve-month EPS dynamics illustrate the current backdrop, where the 19.00 mark serves as a key metric. The company is developing innovative antibodies for long-term monetization through partnerships. High sales potential is supported by a lack of saturation in the niche for drugs targeting resistant forms of cancer.

Sensei Biotherapeutics, Inc. (SNSE) Earnings per share for the last twelve months: for the period 02/11/2024 - 06/16/2026

SNSE (Sensei Biotherapeutics Inc): analytical breakdowns and indicator data

Initial company analysis:SNSE, Sensei Biotherapeutics
Mass-produced product of Sensei Biotherapeutics, Inc.

For an investor in Sensei Biotherapeutics (SNSE), the fundamental valuation of the company depends directly on the dynamics of its ability to generate net earnings per share. Analyzing the current EPS TTM YoY growth rate reveals the percentage change in profit over the year, which, in the context of implementing software robots for express data validation, reflects the efficiency of laboratory process automation and the overall business scaling trajectory.

Direct competitors

Earnings per share for the trailing year IBRX (ImmunityBio)|IMCR: Net earnings per share (EPS TTM)|JANX - Net earnings per share for the last four quarters|Earnings per share for the last twelve months arcusbio.com|Net earnings per share for the last 12 months zymeworks.com (ZYME)|Earnings per share for the last twelve months Tango Therapeutics Inc (TNGX)|Net earnings per share for the last 12 months Iovance IOVA|Immatics NV - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Xencor Inc. XNCR|CMPX - Earnings per share for the last twelve months|REPL (replimune.com) - Earnings per share for the last 12 months|Lyell Pharma (LYEL) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Innate Pharma, S.A. (IPHA)|Net earnings per share for the last 12 months PYXS|CGEN - Net earnings per share for the trailing year|Net earnings per share for the last 12 months IOBT (IO Biotech Corp)|Earnings per share for the last four quarters STRO|Net earnings per share (EPS TTM) INKT (MiNK Therapeutics)|Earnings per share for the trailing year HOWL|Immix - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months ALX Oncology Holdings Inc.|CUE: Net earnings per share (EPS TTM)|PDS Biotech - Earnings per share for the trailing year|SONN (Sonnet BioTherapeutics Holdings Inc.) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) MAIA Biotech|Earnings per share for the last twelve months Liminatus Pharma LLC (LIMN)|LVTX: Earnings per one share for the last 12 months|NextCure Inc - Net earnings per share for the last 12 months|Leap Therapeutics, Inc. (LPTX) - Net earnings per one share for the last twelve months|Intensity Therapeutics Inc - Net earnings per share (EPS TTM)|Theriva Biologics - Earnings per share for the last four quarters|Gritstone Bio (GRTS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Kineta, Inc. (KA)|Net earnings per share for the last 12 months NEXI|TSBX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) VCNX|HARP: Earnings per one share for the last 12 months